LDX in the Treatment of Executive Function Difficulties in Women After Oophorectomy

Trial Profile

LDX in the Treatment of Executive Function Difficulties in Women After Oophorectomy

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Cognition disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 May 2016 Status changed from recruiting to withdrawn prior to enrolment as funding not obtained.
    • 22 Jun 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
    • 26 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top